The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2018

Filed:

Mar. 20, 2017
Applicants:

The Board of Trustees of the University of Illinois, Urbana, IL (US);

Ocugen, Inc., Malvern, PA (US);

Inventors:

Sandeep Jain, Oak Park, IL (US);

Uday Bhaskar Kompella, Englewood, CO (US);

Shankar Musunuri, Chester Springs, PA (US);

Assignees:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 9/107 (2006.01); A61K 47/38 (2006.01); A61K 31/573 (2006.01);
U.S. Cl.
CPC ...
A61K 31/498 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/107 (2013.01); A61K 31/573 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01);
Abstract

The present invention relates to a method for treating a dry eye syndrome using an alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also relates to an ophthalmic composition comprising a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.


Find Patent Forward Citations

Loading…